Literature DB >> 31348575

SMYD2 Drives Mesendodermal Differentiation of Human Embryonic Stem Cells Through Mediating the Transcriptional Activation of Key Mesendodermal Genes.

Hua-Jun Bai1, Peng Zhang1, Li Ma2, He Liang1, Gang Wei2, Huang-Tian Yang1.   

Abstract

Histone methyltransferases play a critical role in early human development, whereas their roles and precise mechanisms are less understood. SET and MYND domain-containing protein 2 (SMYD2) is a histone lysine methyltransferase induced during early differentiation of human embryonic stem cells (hESCs), but little is known about its function in undifferentiated hESCs and in their early lineage fate decision as well as underlying mechanisms. Here, we explored the role of SMYD2 in the self-renewal and mesendodermal lineage commitment of hESCs. We demonstrated that the expression of SMYD2 was significantly enhanced during mesendodermal but not neuroectodermal differentiation of hESCs. SMYD2 knockout (SMYD2-/- ) did not affect self-renewal and early neuroectodermal differentiation of hESCs, whereas it blocked the mesendodermal lineage commitment. This phenotype was rescued by reintroduction of SMYD2 into the SMYD2-/- hESCs. Mechanistically, the bindings of SMYD2 at the promoter regions of critical mesendodermal transcription factor genes, namely, brachyury (T), eomesodermin (EOMES), mix paired-like homeobox (MIXL1), and goosecoid homeobox (GSC) were significantly enhanced during mesendodermal differentiation of SMYD2+/+ hESCs but totally suppressed in SMYD2-/- ones. Concomitantly, such a suppression was associated with the remarkable reduction of methylation at histone 3 lysine 4 and lysine 36 but not at histone 4 lysine 20 globally and specifically on the promoter regions of mesendodermal genes, namely, T, EOMES, MIXL1, and GSC. These results reveal that the histone methyltransferase SMYD2 is dispensable in the undifferentiated hESCs and the early neuroectodermal differentiation, but it promotes the mesendodermal differentiation of hESCs through the epigenetic control of critical genes to mesendodermal lineage commitment. Stem Cells 2019;37:1401-1415. ©AlphaMed Press 2019.

Entities:  

Keywords:  Brachyury; Eomesodermin; Goosecoid homeobox; Histone methyltransferase; Human embryonic stem cells; Mesendodermal differentiation; Mix paired-like homeobox; SET and MYND domain-containing protein 2

Year:  2019        PMID: 31348575     DOI: 10.1002/stem.3068

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  6 in total

1.  Myosin light chain 2 marks differentiating ventricular cardiomyocytes derived from human embryonic stem cells.

Authors:  Xiao-Ling Luo; Peng Zhang; Xiangyuan Liu; Shiqian Huang; Sen-Le Rao; Qiurong Ding; Huang-Tian Yang
Journal:  Pflugers Arch       Date:  2021-05-24       Impact factor: 3.657

2.  SMYD2 facilitates cancer cell malignancy and xenograft tumor development through ERBB2-mediated FUT4 expression in colon cancer.

Authors:  Yanzong Lai; Yang Yang
Journal:  Mol Cell Biochem       Date:  2020-04-27       Impact factor: 3.842

3.  TATA box-binding protein-related factor 3 drives the mesendoderm specification of human embryonic stem cells by globally interacting with the TATA box of key mesendodermal genes.

Authors:  He Liang; Peng Zhang; Hua-Jun Bai; Jijun Huang; Huang-Tian Yang
Journal:  Stem Cell Res Ther       Date:  2020-05-24       Impact factor: 6.832

4.  The Lysine Methyltransferase SMYD2 Is Required for Definite Hematopoietic Stem Cell Production in the Mouse Embryo.

Authors:  Melissa A Edwards; Mark A Brown; Ilham Alshiraihi; Dillon K Jarrell; Haley O Tucker
Journal:  Vet Sci       Date:  2020-07-25

5.  The Lysine Methylase SMYD3 Modulates Mesendodermal Commitment during Development.

Authors:  Raffaella Fittipaldi; Pamela Floris; Valentina Proserpio; Franco Cotelli; Monica Beltrame; Giuseppina Caretti
Journal:  Cells       Date:  2021-05-18       Impact factor: 6.600

6.  A preview of selected articles.

Authors:  Stuart P Atkinson
Journal:  Stem Cells Transl Med       Date:  2021-03       Impact factor: 6.940

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.